Worth reading
62In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
1225
USD million (total of a USD 700 million payment and earnout consideration of up to USD 525 million)Wording
Conditional
How definitive the wording is.This transaction
The acquisitionCounterpartyKevin Ryan, Alpha Wave Ventures II, LP, The Kevin P. Ryan 2012 Trust
Disclosing companyOtsuka Holdings Co.,Ltd.
The voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Contract Date27 March 2026
Execution Date / Effective DateDuring the second quarter of fiscal 2026 (予定)
Target company
Pharmaceutical research and development
Location New York City, New York, United StatesShare capital USD 41,663 thousandDate of incorporation December 2020
Net SalesUSD 0 thousand (fiscal year ended December 2025)
Operating profit(USD 18,240 thousand) (fiscal year ended December 2025)
Net income for the current fiscal year(USD 17,770 thousand) (fiscal year ended December 2025)
Net assets(USD 8,724 thousand) (fiscal year ended December 2025)
Consideration and expenses
Acquisition priceOtsuka will pay USD 700 million, plus up to USD 525 million in earnout consideration upon achievement of revenue-based milestones (estimated amounts).
Type of ConsiderationCash (to be paid to Transcend's existing shareholders)
Impact on Business Performance
The impact of this transaction on Otsuka Pharmaceutical's consolidated earnings forecast for the fiscal year ending December 2026 will be announced once finalized.
Procedures and assumptions
Conditions Precedent to ExecutionCompletion of the necessary procedures and other requirements
Management structure after acquisitionTranscend will become a wholly owned subsidiary and join the Otsuka Pharmaceutical Group. The company name, representative and treatment of employees: not disclosed
| Item | Details |
|---|---|
| Transaction name | The acquisition |
| Counterparty name | Kevin Ryan, Alpha Wave Ventures II, LP, The Kevin P. Ryan 2012 Trust |
| Name of the Subject Company | Transcend Therapeutics, Inc. |
| Business Description of the Subject Company | Pharmaceutical research and development |
| Location of the Subject Company | New York City, New York, United States |
| Capital Stock of the Subject Company | USD 41,663 thousand |
| Date of Establishment of the Subject Company | December 2020 |
| Net Sales of the Subject Company | USD 0 thousand (fiscal year ended December 2025) |
| Operating Profit of the Subject Company | (USD 18,240 thousand) (fiscal year ended December 2025) |
| Net Income of the Subject Company | (USD 17,770 thousand) (fiscal year ended December 2025) |
| Net Assets of the Subject Company | (USD 8,724 thousand) (fiscal year ended December 2025) |
| Acquisition price | Otsuka will pay USD 700 million, plus up to USD 525 million in earnout consideration upon achievement of revenue-based milestones (estimated amounts). |
| Type of Consideration | Cash (to be paid to Transcend's existing shareholders) |
| Number of shares acquired | 20,098,381 common shares and 11,581,923 preferred shares, for a total of 31,680,304 shares (31,680,304 voting rights) |
| Voting rights ownership percentage | Before 0％ → after 100％ |
| Impact on Business Performance | The impact of this transaction on Otsuka Pharmaceutical's consolidated earnings forecast for the fiscal year ending December 2026 will be announced once finalized. |
| Contract Date | 27 March 2026 |
| Execution Date / Effective Date | During the second quarter of fiscal 2026 (予定) |
| Conditions Precedent to Execution | Completion of the necessary procedures and other requirements |
| Management structure after acquisition | Transcend will become a wholly owned subsidiary and join the Otsuka Pharmaceutical Group. The company name, representative and treatment of employees: not disclosed |
Items this document does not state (12)
Expenses other than the acquisition priceMerger ratio/share exchange ratioTender offer priceMinimum number of shares to be purchasedTender offer periodFunding arrangementsGoodwill amountAmount of extraordinary income (loss)Date of board resolutionValuation methodologyIndependent valuation institutionSpecial Committee
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The acquisition will enable Otsuka Pharmaceutical to obtain TSND-201, which has a mechanism of action different from those of the drugs and development-stage products it already owns, and expand its product portfolio in the psychiatric and neurological fields. In particular, Otsuka aims to accelerate the development of next-generation treatments, including for PTSD, and increase treatment options.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.